as mentioned in upi
FDA issues warning against widely used ovarian cancer screening test
FDA issues warning against widely used ovarian cancer screening test
SILVER SPRING, Md., Sept. 8 (UPI) -- The U.S. Food and Drug Administration issued a warning today that there are no proven methods of screening for ovarian cancer, stressing caution to both patients and doctors about making treatment decisions based on any test for the disease.The FDA warning comes as the company Abcodia, maker of the Risk of Ovarian Cancer Algorithm, or RICA, ovarian cancer screen, announced in a press release it would be making its test available nationwide by the end of the year.The agency is concerned women or their doctors could make decisions to treat cancer based on false-positive test results, or opt to delay treatment based on a false-negative -- with either path carrying negative consequences for patients, the FDA said.The National Cancer Institute estimates more than 22,000 women will be diagnosed with ovarian cancer this year, with women who have reached menopause, those with family history of the disease and women with the BRCA1 and BRCA2 genetic mutations at highest risk for its development.
moreover from consumeraffairs
Be wary of home testing kits for ovarian cancer
Be wary of home testing kits for ovarian cancer
A former reporter and bureau chief for broadcast outlets and magazines, Truman Lewis has covered presidential campaigns, state politics and stories ranging from organized crime to environmental protection.Read Full Bio→There are home testing kits for all kinds of medical conditions.Some are better than others and some are no good at all.And that, says the FDA, describes home testing kits for ovarian cancer.
in like manner foxnews
FDA warns against widely used ovarian cancer screening test
FDA warns against widely used ovarian cancer screening test
WASHINGTON — The Food and Drug Administration on Wednesdaywarned women and their doctors that current screening tests for ovarian cancer are unreliable and could lead to false diagnoses.In a statement, the FDA said it was "especially concerned about delaying effective preventive treatments for women who show no symptoms, but who are still at increase risk of ovarian cancer."Ovarian cancer is the fifth-leading cause of cancer-related deaths among women.The National Cancer Institute estimates that this year more than 22,000 women between ages 35 and 74 will be diagnosed with the disease.Those at highest risk are women who have reached menopause, those who have a family history of ovarian cancer, and women with the BRCA1 or BRCA2 genetic mutations.